leflunomide has been researched along with canertinib dihydrochloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Belsey, JD; Brack, K; Bulle, A; Chen, Z; Fluck, D; John, I; Kodre, A; Kralj-Hans, I; Lamorgese, A; Li, HL; Li, K; Li, L; Li, S; Marczin, N; McGee, M; Omar, F; Ranasinghe, K; Seshasai, SRK; Sharma, P; Sharma, S; Wesek, A | 1 |
1 trial(s) available for leflunomide and canertinib dihydrochloride
| Article | Year |
|---|---|
Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Topics: Adult; Aged; COVID-19; Female; Humans; Leflunomide; Male; Middle Aged; Oxygen; Prospective Studies; SARS-CoV-2; Treatment Outcome | 2023 |